These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27481574)

  • 1. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.
    Crivianu-Gaita V; Rivard GE; Carcao M; Teitel J; St-Louis J; Blanchette V; Pullenayegum E; Abad A; Feldman BM
    Haemophilia; 2016 Sep; 22(5):e401-5. PubMed ID: 27481574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A.
    Sun HL; McIntosh KA; Squire SJ; Yang M; Bartholomew C; Gue DS; Camp PG; Jackson SC
    Haemophilia; 2017 Nov; 23(6):877-883. PubMed ID: 28851133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
    Lindvall K; Astermark J; Björkman S; Ljung R; Carlsson KS; Persson S; Berntorp E
    Haemophilia; 2012 Nov; 18(6):855-9. PubMed ID: 22681244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.
    Wu R; Sun J; Xiao J; Liu Y; Xue F; Wang H; Tang L; Zhao Y; Li K; Yang R; Hu Y; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL
    Haemophilia; 2017 May; 23(3):430-436. PubMed ID: 28345299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK-guided personalized prophylaxis with Nuwiq
    Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
    Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
    Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
    Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
    Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
    Hua B; Lee A; Fan L; Li K; Zhang Y; Poon MC; Zhao Y
    Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
    Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
    Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients.
    Arvanitakis A; Jepsen C; Andersson NG; Baghaei F; Astermark J
    Haemophilia; 2024 May; 30(3):671-677. PubMed ID: 38575549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A; Oldenburg J; Lissitchkov T; Knaub S; Bichler J; Manco-Johnson MJ
    Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
    Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
    Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
    Oldenburg J; Tran H; Peyvandi F; Núñez R; Trask P; Chebon S; Mahlangu JN; Lehle M; Jiménez-Yuste V; von Mackensen S
    Haemophilia; 2021 May; 27(3):398-407. PubMed ID: 33576546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.